GATC Biotech's GATCLiquid

GATC Biotech has released a new liquid biopsy offering for early-access clinical research and product development called GATCLiquid Technology Suite. Based on next-gen sequencing and GATC's proprietary analysis techniques, the suite is aimed at the detection of genomic alterations in circulating DNA for diagnostic purposes, such as identifying clinically actionable genomic alterations that influence tumor development or treatment outcomes.

GATC says it has already sequenced more than 40,000 samples from blood and plasma, the majority under diagnostic conditions.